Interview with CEO Michelle Teng in Inside Precision Medicine

Etcembly co-founder Michelle Teng talks to Helen Albert about her journey in science and how we're building the next generation of AI-designed TCR immunotherapies.

https://www.insideprecisionmedicine.com/topics/oncology/building-t-cell-receptor-therapies-with-generative-ai/ 

Etcembly CEO and co-founder Michelle Teng